Activated TRPA1 plays a therapeutic role in TMZ resistance in glioblastoma by altering mitochondrial dynamics

Glioblastoma (GBM) represents nearly one-half of primary brain tumors, and the median survival of patients with GBM is only 14.6  months. Surgery followed by radiation with concomitant temozolomide (TMZ) therap...

Source: BMC Cell Biology - August 19, 2022 Category: Cytology Authors: Hao Chen, Chunlin Li, Haiyang Hu and Bin Zhang Tags: Research Source Type: research